The EHBP1L1 Knockout SK-HEP-1 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population generated from the human SK-HEP-1 cell line. This product features targeted disruption of the EHBP1L1 gene, resulting in a loss-of-function model suitable for investigating the adaptor’s role in endocytic trafficking. EHBP1L1 functions as a linker between EHD proteins and the actin cytoskeleton, and its disruption enables detailed study of receptor recycling pathways in a liver cancer context.
SK-HEP-1 is a well-characterized human hepatocellular carcinoma cell line originally isolated from the ascitic fluid of a patient with liver adenocarcinoma. These cells are widely employed as a model system for studying liver cancer biology, including mechanisms of tumor progression, metastasis, and drug response. Their epithelial origin and malignant properties make SK-HEP-1 particularly valuable for exploring the contributions of endocytic trafficking to hepatocellular carcinoma pathology.
At the molecular level, EHBP1L1 serves as an adaptor that bridges EHD1 and EHD2 with the actin cytoskeleton, thereby coordinating clathrin-mediated endocytosis and subsequent endocytic recycling. It interacts directly with components of the clathrin and AP-2 complexes, and is essential for the efficient recycling of the transferrin receptor (TfR) and the epidermal growth factor receptor (EGFR) back to the plasma membrane. By modulating the surface levels of these receptors, EHBP1L1 influences downstream signaling pathways activated by transferrin and EGF, which in turn regulate actin dynamics and cell migration.
In the SK-HEP-1 hepatocellular carcinoma background, loss of EHBP1L1 is anticipated to compromise the recycling of EGFR and TfR, leading to altered receptor signaling that may affect tumor cell behavior. Given that EGFR signaling drives proliferation and survival in many cancers, and that transferrin receptor cycling is crucial for iron uptake, the knockout model allows researchers to test directly how endocytic defects influence hepatocellular carcinoma cell growth, migration, and invasion. This model thus provides a powerful tool for linking EHBP1L1 function to cancer cell phenotypes and for evaluating its potential as a therapeutic target.
This polyclonal knockout cell population is suitable for a range of experimental approaches, including Western blotting and RT-qPCR for confirming loss of EHBP1L1 expression, transferrin uptake assays and EGFR recycling biotinylation to quantify endocytic trafficking efficiency, and migration and invasion assays to assess metastatic potential. Immunofluorescence microscopy can be employed to examine the colocalization of EHD1 with actin, shedding light on cytoskeletal reorganization following EHBP1L1 disruption. These applications support functional genomics studies, investigation of receptor trafficking in hepatocellular carcinoma, and broader research into endocytic recycling mechanisms. For further details, please contact Ascent Research.
